Tecfidera and MRI for Brain Energy in MS
Modulation of Cerebral Grey Matter High Energy Phosphate Metabolites in Multiple Sclerosis by Dimethyl Fumarate
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosis of MS by 2010 McDonald criteria
- Relapsing clinical course
- Ages 18-55
- Laboratory values that allow initiation of dimethyl fumarate (Tecfidera)
Exclusion Criteria:
- Systemic disease associated with cerebrovascular disease (e.g. diabetes mellitus, hypertension, hyperlipidemia, coronary heart disease)
- Treatment with corticosteroids or disease-modifying therapies (interferon beta, glatiramer acetate, natalizumab, fingolimod, teriflunomide) within 30 days of the first baseline MRI scan.
- Treatment at any time with mitoxantrone, cyclophosphamide, or any other long acting immunosuppressant
- Prior treatment of greater than 1 month at any time with DMF
- Inability to tolerate MRI procedures
- Pregnant/breastfeeding
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in phosphocreatine (PCr) in cerebral grey matter
Time Frame: baseline and 6 months of treatment with Dimethyl Fumarate (DMF)
|
PCr levels evaluated by magnetic resonance spectroscopy
|
baseline and 6 months of treatment with Dimethyl Fumarate (DMF)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in ATP in normal appearing white matter (NAWM)
Time Frame: baseline and 6 months of treatment with Dimethyl Fumarate
|
ATP levels evaluated by magnetic resonance spectroscopy
|
baseline and 6 months of treatment with Dimethyl Fumarate
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in fatigue
Time Frame: baseline and 6 months of treatment with DMF
|
as assessed by Fatigue Severity Scale (FSS), Modified Fatigue Impact Scale (MFIS),
|
baseline and 6 months of treatment with DMF
|
|
Changes in fatigue
Time Frame: baseline and 6 months of treatment with DMF
|
as assessed by Modified Fatigue Impact Scale (MFIS),
|
baseline and 6 months of treatment with DMF
|
|
Changes in cognition
Time Frame: baseline and 6 months of treatment with DMF
|
as assessed by the symbol digit modalities test (SDMT)
|
baseline and 6 months of treatment with DMF
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Rebecca Spain, MD, MSPH, Oregon Health and Science University
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Multiple Sclerosis
- Sclerosis
- Physiological Effects of Drugs
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Dimethyl Fumarate
Other Study ID Numbers
Other Study ID Numbers
- IRB 11364
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.